About River BioMedics

This company develops novel therapies for cardiovascular diseases by focusing on direct targeting of the heart muscle. They utilize expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to create advanced 3D cardiac in vitro models. These models support the discovery and development pipeline for new cardiac drugs.

```xml <problem> Traditional methods of pre-clinical cardiac drug testing often fail to accurately predict drug responses in humans, leading to costly late-stage failures in clinical trials. Existing 2D cell cultures and animal models do not fully replicate the complex 3D structure and function of the human heart, resulting in inaccurate assessments of drug efficacy and toxicity. </problem> <solution> River BioMedics develops advanced 3D in vitro human cardiac models utilizing human induced pluripotent stem cells (hiPSC) to provide more predictive and clinically relevant platforms for cardiac drug discovery. Their portfolio includes a 3D Cardiac Strip, Heart-on-a-Chip, and Mini-Heart, each designed to mimic the structure and function of the human heart muscle. These models enable researchers to directly target the heart muscle and obtain detailed, clinically relevant read-outs, enhancing the efficiency of therapeutic development for cardiovascular diseases. River BioMedics' technology aims to bridge the gap between pre-clinical testing and clinical outcomes, reducing the risk of late-stage drug failures. </solution> <features> - 3D Cardiac Strip: A multicellular cardiac tissue construct for evaluating contractile force and electrophysiological activity. - Heart-on-a-Chip: A microfluidic device that replicates the physiological microenvironment of the human heart, enabling real-time monitoring of cardiac function. - Mini-Heart: A miniaturized 3D cardiac model that mimics the structural and functional properties of the human heart, suitable for high-throughput screening. - hiPSC-derived cardiomyocytes: Models are created using human induced pluripotent stem cells, ensuring human-relevant cardiac tissue. - Clinically relevant read-outs: Provides detailed data on cardiac function, including contractility, electrophysiology, and calcium handling. - High-throughput screening: Enables efficient screening of drug candidates, accelerating the drug discovery process. </features> <target_audience> The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in cardiac drug discovery and development. </target_audience> ```

What does River BioMedics do?

Where is River BioMedics located?

River BioMedics is based in Enschede, The Netherlands.

When was River BioMedics founded?

River BioMedics was founded in 2018.

How much funding has River BioMedics raised?

River BioMedics has raised $4.3M.

Who founded River BioMedics?

River BioMedics was founded by Nicky Cooper.

Nicky Cooper - CEO

Location

Enschede, The Netherlands

Founded

2018

Funding

$4.3M

Employees

16 employees

Investors

Biogeneration Ventures Kikk Capital

River BioMedics

Enschede, The NetherlandsFounded 2018161K+ followers8/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 19 months ago

Funding

$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Traditional methods of pre-clinical cardiac drug testing often fail to accurately predict drug responses in humans, leading to costly late-stage failures in clinical trials. Existing 2D cell cultures and animal models do not fully replicate the complex 3D structure and function of the human heart, resulting in inaccurate assessments of drug efficacy and toxicity.

Solution

River BioMedics develops advanced 3D in vitro human cardiac models utilizing human induced pluripotent stem cells (hiPSC) to provide more predictive and clinically relevant platforms for cardiac drug discovery. Their portfolio includes a 3D Cardiac Strip, Heart-on-a-Chip, and Mini-Heart, each designed to mimic the structure and function of the human heart muscle. These models enable researchers to directly target the heart muscle and obtain detailed, clinically relevant read-outs, enhancing the efficiency of therapeutic development for cardiovascular diseases. River BioMedics' technology aims to bridge the gap between pre-clinical testing and clinical outcomes, reducing the risk of late-stage drug failures.

Target Audience

The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in cardiac drug discovery and development.

Features

3D Cardiac Strip: A multicellular cardiac tissue construct for evaluating contractile force and electrophysiological activity.
Heart-on-a-Chip: A microfluidic device that replicates the physiological microenvironment of the human heart, enabling real-time monitoring of cardiac function.
Mini-Heart: A miniaturized 3D cardiac model that mimics the structural and functional properties of the human heart, suitable for high-throughput screening.
hiPSC-derived cardiomyocytes: Models are created using human induced pluripotent stem cells, ensuring human-relevant cardiac tissue.
Clinically relevant read-outs: Provides detailed data on cardiac function, including contractility, electrophysiology, and calcium handling.
High-throughput screening: Enables efficient screening of drug candidates, accelerating the drug discovery process.